Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Nanjing University School of Medicine Sun Yat-sen University |
---|---|
Information provided by: | Nanjing University School of Medicine |
ClinicalTrials.gov Identifier: | NCT00302549 |
Condition | Intervention |
---|---|
Lupus Nephritis |
Drug: FK506 |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | To Compare the Efficacy and Safety of FK506 vs IVC in the Treatment of Class |
Enrollment: | 61 |
Study Start Date: | May 2004 |
Study Completion Date: | February 2006 |
Primary Completion Date: | May 2005 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
2: Active Comparator
CTX
|
Drug: FK506
FK506,0.1mg/kg/d
|
Corticosteroid combined with cytotoxic drugs has been regarded as the conventional therapy for Class IV Lupus Nephritis (LN), because of its efficacy in improving patients' long term survival. However, this treatment fails in some patients, especially those who present with significant vascular lesion. In addition, cyclophosphamide (CTX) has severe side effects with a high incidence of marrow inhibition and infection.FK506 (Tacrolimus) is a new calcineurin inhibitor. Similar to Cyclosporine (CsA), it inhibits the production of IL-2 and activation of T cells. Furthermore, it has an added value of inhibiting the production of IL-10 from Th2 cells, thus reducing the production of auto antibodies from B cells.It also exerts its specific immunosuppressive effects through CsA-insensitive pathway. FK506 could inhibit not only the activation of naive T cells but also the activation and proliferation of primed T cells.FK506 is 10 -100 times more powerful than CsA in inhibiting the activation of T cells.Animal studies on MRL/lpr mice LN model demonstrated that FK506 could significantly depress the excretion of urine protein and the level of serum anti-dsDNA, inhibit glomerular cellular proliferation and formation of crescents, and reduce the deposits of immune complex.
A preliminary study showed that FK506 was significantly effective on patients with IV LN,as indicated by rapid reduction of urine protein, increase in serum albumin, decrease in auto antibodies together with remission of lesion activity of the renal tissue. However, the drawbacks of this study were the small sample size and the lack of a controlled group. Hence, a multi-center controlled study comparing FK506 with cytotoxic agents to evaluate the efficacy and safety of FK506 on patients with III or IV LN, and explore the effective range of FK506 blood concentration and the appropriate target patient population would be needed.
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
China, Jiangsu | |
Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine | |
Nanjing, Jiangsu, China, 210002 |
Study Director: | Lei-shi Li, M.D. | Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine |
Responsible Party: | Nanjing University School of Medicine ( Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine ) |
Study ID Numbers: | NJCT-0602 |
Study First Received: | March 13, 2006 |
Last Updated: | July 14, 2008 |
ClinicalTrials.gov Identifier: | NCT00302549 |
Health Authority: | China: State Food and Drug Administration |
Tacrolimus Cyclophosphamide Treatment Lupus Nephritis |
Glomerulonephritis Autoimmune Diseases Lupus Erythematosus, Systemic Urologic Diseases Lupus Nephritis |
Nephritis Connective Tissue Diseases Tacrolimus Cyclophosphamide Kidney Diseases |
Immunologic Factors Immune System Diseases Physiological Effects of Drugs Immunosuppressive Agents Pharmacologic Actions |